MacRae F Linton Selected Research

Atherosclerosis (Atheroma)

08/2008	Lentiviral transduction of apoAI into hematopoietic progenitor cells and macrophages: applications to cell therapy of atherosclerosis.
04/2008	Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice.
09/2007	Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
08/2007	Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.
06/2007	Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2.
03/2007	Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse.
01/2006	Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice.
01/2006	Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI double-knockout mice.
08/2005	Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice.
05/2005	Reduced ABCA1-mediated cholesterol efflux and accelerated atherosclerosis in apolipoprotein E-deficient mice lacking macrophage-derived ACAT1.
01/2005	Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice.
11/2004	Angiotensin II amplifies macrophage-driven atherosclerosis.
09/2004	Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice.
04/2004	Cyclooxygenase-2 and inflammation in atherosclerosis.
12/2003	Apolipoprotein AI as therapy for atherosclerosis: does the future of preventive cardiology include weekly injections of the HDL protein?
10/2003	Macrophage apolipoprotein A-I expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters.
11/2002	B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice.
10/2002	Cyclooxygenase-2 and atherosclerosis.
10/2002	Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice.
04/2002	Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis.

Articles by Research Topic

Disease

20	Atherosclerosis (Atheroma) 08/2008 - 04/2002
1	Coronary Disease (Coronary Heart Disease) 09/2006
1	Coronary Artery Disease (Coronary Atherosclerosis) 06/2005
1	Inflammation 04/2004
1	Hyperlipidemias (Hyperlipidemia) 03/2004
1	Fibrosis (Cirrhosis) 12/2002
1	Hypercholesterolemia 10/2002

Drug/Important Bio-Agent (IBA)

5	LDL Receptors (LDL Receptor)IBA 09/2007 - 11/2002
5	ApolipoproteinsIBA 01/2006 - 09/2004
3	Carrier Proteins (Binding Protein)IBA 06/2007 - 10/2002
2	CholesterolIBA 09/2006 - 05/2005
2	Scavenger Receptors (Scavenger Receptor)IBA 01/2006 - 06/2005
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2004 - 10/2002
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 12/2003 - 10/2003
2	Apolipoproteins E (ApoE)IBA 10/2003 - 10/2002
1	Fibronectins (Fibronectin)IBA 04/2008
1	PPAR alphaIBA 09/2007
1	AngiotensinsIBA 08/2007
1	LDL-Receptor Related Protein 1 (LDL-Receptor Related Protein)IBA 03/2007
1	Cyclooxygenase 1IBA 01/2006
1	PPAR gammaIBA 08/2005
1	Angiotensin IIIBA 11/2004
1	Clofibric Acid (Fibrates)IBA 03/2004
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 10/2003
1	Type 1 Angiotensin ReceptorIBA 12/2002
1	Fatty Acid-Binding ProteinsIBA 04/2002

Therapy/Procedure

1	Tissue Therapy (Cell Therapy) 08/2008